{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:56:21Z","timestamp":1792652181796,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.14283\/jpad.2024.159","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T01:40:42Z","timestamp":1724809242000},"page":"1549-1562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center"],"prefix":"10.1016","volume":"11","author":[{"given":"L.B.E.","family":"Shields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"Cooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.N.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.C.","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.W.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.Y.","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Wasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.T.","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.B.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.S.","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth G.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2024.159_bib1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis."},{"key":"10.14283\/jpad.2024.159_bib2","doi-asserted-by":"crossref","first-page":"100657","DOI":"10.1016\/j.lanepe.2023.100657","article-title":"The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint","volume":"29","author":"Jonsson","year":"2023","journal-title":"Lancet Reg Health Eur."},{"key":"10.14283\/jpad.2024.159_bib3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.17219\/acem\/171379","article-title":"Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease","volume":"32","author":"Kurkinen","year":"2023","journal-title":"Adv Clin Exp Med."},{"key":"10.14283\/jpad.2024.159_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther."},{"key":"10.14283\/jpad.2024.159_bib5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"10.14283\/jpad.2024.159_bib6","author":"Teli"},{"key":"10.14283\/jpad.2024.159_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med."},{"key":"10.14283\/jpad.2024.159_bib8","doi-asserted-by":"crossref","first-page":"100982","DOI":"10.1016\/j.xcrm.2023.100982","article-title":"Lecanemab reduces brain amyloid-beta and delays cognitive worsening","volume":"4","author":"Knopman","year":"2023","journal-title":"Cell Rep Med."},{"key":"10.14283\/jpad.2024.159_bib9","author":"Stewart"},{"key":"10.14283\/jpad.2024.159_bib10","doi-asserted-by":"crossref","first-page":"1169499","DOI":"10.3389\/fnagi.2023.1169499","article-title":"Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meat-analysis of randomized clinical trials","volume":"15","author":"Qiao","year":"2023","journal-title":"Front Aging Neurosci."},{"key":"10.14283\/jpad.2024.159_bib11","doi-asserted-by":"crossref","first-page":"e12377","DOI":"10.1002\/trc2.12377","article-title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease","volume":"9","author":"Honig","year":"2023","journal-title":"Alzheimer's Dement."},{"key":"10.14283\/jpad.2024.159_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bmj.p73","article-title":"Alzheimer's disease: FDA approves lecanemab amid cost and safety concerns","volume":"380","author":"Mahase","year":"2023","journal-title":"BMJ."},{"key":"10.14283\/jpad.2024.159_bib13","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1212\/WNL.0000000000207757","article-title":"Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in Neurology","volume":"101","author":"Ramanan","year":"2023","journal-title":"Neurology."},{"key":"10.14283\/jpad.2024.159_bib14","doi-asserted-by":"crossref","first-page":"e230009","DOI":"10.1148\/rg.230009","article-title":"Amyloid-related imaging abnormalities in Alzheimer disease treated with anti-amyloid-beta therapy","volume":"43","author":"Agarwal","year":"2023","journal-title":"Radiographics."},{"key":"10.14283\/jpad.2024.159_bib15","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.3174\/ajnr.A7586","article-title":"Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice","volume":"43","author":"Cogswell","year":"2022","journal-title":"AJNR Am J Neuroradiol."},{"key":"10.14283\/jpad.2024.159_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/alz.12372","article-title":"State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease","volume":"18","author":"Hampel","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.14283\/jpad.2024.159_bib17","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1002\/alz.13721","article-title":"Importance of cerebrospinal fluid (CSF) collection protocol for the accurate diagnosis of Alzheimer's disease when using CSF biomarkers","volume":"20","author":"Algeciras-Schimnich","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.14283\/jpad.2024.159_bib18","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/alz.12316","article-title":"The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau","volume":"17","author":"Hansson","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.14283\/jpad.2024.159_bib19","author":"Shaw"},{"key":"10.14283\/jpad.2024.159_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/d41586-023-00030-3","article-title":"FDA approves Alzheimer's drug lecanemab amid safety concerns","volume":"613","author":"Reardon","year":"2023","journal-title":"Nature"},{"key":"10.14283\/jpad.2024.159_bib21","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke","volume":"388","author":"Reish","year":"2023","journal-title":"N Engl J Med."},{"key":"10.14283\/jpad.2024.159_bib22","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","article-title":"Fatal iatrogenic cerebral beta-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease","volume":"14","author":"Solopova","year":"2023","journal-title":"Nat Commun."}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:15:36Z","timestamp":1737321336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724006861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2274580724006861"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2024.159","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2024.159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}